Table 2 Patient characteristics by breast cancer subtype (Number = 819).
Variable | All patients (Number = 819) | HR+/HER2- (Number = 574)(%) | HR+/HER2+ (Number = 57)(%) | HR-/HER2+ (Number = 51)(%) | HR-/HER2- (Number = 94)(%) | P-value |
|---|---|---|---|---|---|---|
Median age at diagnosis | 55 | 56 | 54 | 49 | 54 | < 0.01 |
T1 | 615 | 439 (76.48) | 41 (71.93) | 36 (70.59) | 60 (63.83) | 0.06 |
Positive lymph nodes | 230 | 164 (28.57) | 25 (43.86) | 14 (27.45) | 19 (20.21) | 0.02 |
≥ 4 positive lymph nodes | 10 | 7 (1.22) | 0 | 0 | 3 (3.19) | 0.25 |
Lymphovascular invasion | 137 | 89 (15.51) | 16 (28.07) | 13 (25.49) | 16 (17.02) | 0.07 |
Modified Black's nuclear grade 3 | 301 | 132 (23.00) | 36 (63.16) | 48 (94.12) | 75 (79.79) | < 0.01 |
Close or positive margins | 27 | 17 (2.96) | 0 | 3 (5.88%) | 5 (5.32) | 0.21 |
Hormonal therapy | 556 | 473 (82.40) | 50 (87.72) | 5 (9.80) | 6 (6.38) | < 0.01 |
Chemotherapy | 390 | 235 (40.94) | 42 (73.68) | 38 (74.51) | 64 (68.09) | < 0.01 |
Median follow-up (months) | 58 | 58 | 55 | 62 | 53 | 0.11 |
Locoregional recurrence incidence rate at 60 months (95%CI) | 2.5% (1.6% to 4.0%) | 1% (0.1% to 1.9%) | 6.5% (0 to 13.5%) | 2% (0 to 5.8%) | 10.9% (3.8% to 17.5%) | < 0.01 |
Local recurrence incidence rate at 60 months (95% CI) | 0.9% (0.5% to 2.1%) | 0.5% (0.2% to 1.7%) | 4.7% (2.3% to 17.7%) | 0% | 2.6% (0.7% to 10.5%) | 0.06 |
Regional recurrence incidence rate at 60 months (95% CI) | 1.5% (0.9% to 2.8%) | 0.5% (0.2% to 2.0%) | 1.8% (0.3% to 12.1%) | 2.0% (0.3% to13.4%) | 8.3% (4.2% to 16.1%) | < 0.01 |